NR5A2 and type 1 diabetes mellitus: Our findings also reveal that MDMs and DCs from healthy donors respond differently to the pharmacological activation of LRH‐1/NR5A2 compared with those from individuals with T1D, underscoring fundamental molecular alterations caused by the disease.